Kosco-Vilbois will bring much knowledge and understanding to the Swiss-based company, coming from the same position at Novimmune, with many years of experience in clinical trials and drug development.
Integrating into the company with the help of Dr David Lowe, the interim leader of the research team, Kosco-Vilbois will be working on the broad pipeline focused on neurodegenerative diseases.
The new Chief Scientific Officer’s expertise in drug development comes from her roles as Head of Immunology and Preclinical Pharmacology at the Serono Pharmaceutical Research Institute, a Senior Scientist and then Head of Immunology at the Glaxo Wellcome Research Institute in Geneva and a then a Scientific Member of the Basel Institute for Immunology.
Her most notable project thus far has been the Biological for an Orphan indication. A project focused on aiding those with rare or ‘orphan’ diseases.
Kosco-Vilbois will be reporting to CEO Andrea Pfeifer, who said: “I am delighted to welcome Dr. Marie Kosco-Vilbois as our Chief Scientific Officer. The Company will benefit greatly from her extensive experience in Immunology and Drug Development, which will enhance growth of the Company's robust pipeline in Neurodegenerative Diseases."
